Orchid Pharma Limited reported a standalone net profit of ₹45 crore for FY26, a decline of 58% from ₹106 crore in the previous year. Revenue from operations for the year stood at ₹811 crore, down 12% from ₹922 crore in FY25. The board approved the audited standalone and consolidated financial results at its meeting held on May 25, 2026. The company released its investor presentation for Q4FY26 on May 26, 2026, detailing its transition from turnaround to platform creation.

Quarterly Financial Performance

For the quarter ended March 31, 2026, Orchid Pharma reported a standalone net profit of ₹31 crore, compared to ₹28 crore in the same quarter last year. Revenue from operations for the quarter was ₹238 crore, marginally higher than ₹237 crore in Q4 FY25. EBITDA for the quarter rose 5% to ₹42 crore, with the EBITDA margin expanding to 17% from 16% year-on-year. The statutory auditors, M/s. Singhi & Co., issued an unmodified opinion on the standalone financial results.

The following table summarises the key standalone and full-year financial metrics:

Consolidated Results

On a consolidated basis, the net profit for FY26 was ₹205.47 crore, a significant decline from ₹996.57 crore in the previous year. Revenue from operations for the consolidated entity was ₹811.33 crore for the year. M/s. Singhi & Co. expressed a modified opinion on the consolidated results due to the inclusion of unaudited financial statements of certain subsidiaries, specifically Orchid Pharmaceuticals Inc., USA; Bexel Pharmaceuticals Inc., USA; and Diakron Pharmaceuticals, Inc. USA.

Corporate Governance and Strategy

The board appointed M/s. T R Chadha & Co., LLP as the internal auditor for the financial year 2026-27. Additionally, the company reversed an exceptional item of ₹53.92 lakh in the March 2026 quarter, which was previously provided for incremental liabilities related to new Labour Codes. The trading window closure, which was in effect since April 01, 2026, will remain closed until 48 hours after the declaration of the financial results.

Orchid Pharma outlined its capital allocation plan, prioritising the integration of 7-ACA to reduce import dependence. The company plans to invest ₹750 crore in TACA and downstream integration, targeting a commissioning in FY27. It also committed ₹200 crore to the Cefiderocol Access Project to build 1 million vials capacity and ₹50 crore for FDF capability and filings to support 5-6 sterile US launches by 2030.

Orchid Pharma Limited has announced the schedule for its analysts and investors earnings call to discuss the financial performance for the fourth quarter and financial year ended March 31, 2026. The conference is set to take place on Tuesday, May 26, 2026, at 4:30 PM IST. The session is being hosted by Systematix Institutional Equities.

Management Participation

The company's management team will be represented by key executives during the call. The participants include Mr. Manish Dhanuka, Managing Director; Mr. Mridul Dhanuka, Whole Time Director; and Mr. Sunil Kumar Gupta, Chief Financial Officer. They will address the financial results and answer queries from analysts and investors.

Dial-in Details

Participants can join the conference call using the dial-in numbers provided below. A Diamond Pass service is also available for connection without operator assistance.

Additional Information

The information regarding the earnings call will be hosted on the company's official website. The schedule is subject to change due to exigencies, and any modifications will be communicated accordingly. Investors can contact Systematix Institutional Equities for further details regarding the event.